-
• Prof Heather Pinkett and Dr Dafydd Owen to lead ELRIG’s flagship event
• Drug Discovery returns to Liverpool, 21–22 October 2025 to celebrate “A Festival of Life Science”
• Event supported by VisitBritain showcases UK life science sector and extends international reach
May 8, 2025
-
Longhorn Vaccines and Diagnostics Validates Efficacy of PrimeStore® Molecular Transport Medium (MTM) to Inactivate Deadly Pathogens in NIH Study
May 7, 2025
-
Sunnen's cutting-edge bore gaging system offers unmatched precision, versatility, and efficiency for high-precision measurement needs in medical device manufacturing.
May 7, 2025
-
Proscia's Concentriq AP-Dx*software platform was recognized for innovation, performance, value, and impact as digital pathology increasingly enters the mainstream.
May 7, 2025
-
May 7, 2025
-
The findings from the newly presented research suggest that earlier diagnosis through interventions such as Dxcover’s proprietary PANAROMIC™ liquid biopsy platform has the potential to reduce the risk of brain cancer mortality by 18-28%.
The data was presented on 30 April at the Cancer in Primary Care Research International (Ca-PRI) Conference 2025 and the American Association of Cancer Research (AACR) Annual Meeting 2025.
These world first findings use data from a retrospective cohort study of 1,196 patients.
Apr 30, 2025
-
Gifthealth, a technology-driven pharmacy care company dedicated to making prescription access easier and more affordable, is pleased to announce the appointment of Chip Parkinson as its new Chief Executive Officer.
Apr 28, 2025
-
Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, today announced their collaboration with the Child Neurology Society (CNS) as an official 2025-2026 genetic testing partner. For patients and families facing neurodevelopmental disorders (NDD), epilepsy, and other neurological concerns, comprehensive genetic testing is an important step to ending the diagnostic odyssey.
Apr 27, 2025
-
Apr 27, 2025
-
SPINEstat™, a novel, first-in-class diagnostic blood test for axial spondyloarthritis (axSpA), has received UKCA marking and is now listed as an IVD in the United Kingdom. This milestone expands access to an important new tool that addresses the long-standing diagnostic challenges associated with axSpA. AxSpA is an inflammatory autoimmune condition of the spine, often misdiagnosed as persistent lower back pain for 7–10 years before accurate detection. Earlier diagnosis is essential to prevent irreversible spinal damage and to improve outcomes. SPINEstat™ offers physicians an objective, clinically validated biomarker to support early and accurate axSpA diagnosis, marking a major advancement in autoimmune diagnostics across the UK.
Apr 22, 2025
-
Apr 22, 2025
-
Predictive Power of IsoPSA Is Sustained For Over Two Years; Data Strengthens Evidence for IsoPSA’s Accuracy in Prostate Cancer Detection & Patient Risk Assessment
Apr 22, 2025
-
Hospital-acquired infections (HAIs) remain a major concern in healthcare, causing significant morbidity, mortality, and increased hospital costs. Despite advancements in infection control, HAIs continue to affect millions of patients annually, often due to antibiotic-resistant pathogens.
Apr 21, 2025
-
SPINEstat™, a novel, first-in-class diagnostic blood test for axial spondyloarthritis (axSpA), has been approved by Health Canada. This approval marks an important milestone in addressing a significant global unmet need in axSpA. As an inflammatory autoimmune condition impacting the spine, axSpA often goes undiagnosed, mistaken for persistent lower back pain for 7-10 years before an accurate diagnosis. There is an urgent need to decrease the diagnostic delay for axSpA. If untreated, axSpA is a highly debilitating disease that causes irreversible spinal fusion leading to reduced mobility and quality of life. It can strike at any age, but typically begins before age 45, during the most productive years of a person’s life.
Apr 15, 2025
-
Apr 16, 2025
-
CluePoints, provider of leading statistical and AI-driven software solutions, has been named as a finalist in the ‘Innovative Clinical Trial Solutions’ category at the 2025 Citeline Awards.
Apr 14, 2025
-
VieCure is making thousands of the most commonly used NCCN Chemotherapy Order Templates available on its Halo Intelligence Platform
Apr 14, 2025
-
Oxford Nanopore Technologies announced the expansion of its Compatible Products Program. New participating companies include: 10x Genomics, Agilent Technologies, Asuragen, Day Zero Diagnostics, Hamilton Robotics, NEB, Opentrons, Pathosense, and Thermo Fisher Scientific.
Apr 13, 2025
-
Phastar, a global specialist biometrics & data science Contract Research Organization (CRO), has been shortlisted in the ‘CRO Partnership of the Year’ category at the 2025 Citeline Awards for its collaboration with Medicines Development for Global Health (MDGH), a not for profit pharmaceutical company dedicated to the development of affordable medicines for the people who need them most.
Apr 9, 2025
-
Apr 7, 2025